Latest News & Features
Big Pharma
Moderna alleges that rivals’ vaccine infringes patents filed covering a foundational mRNA technology | Big pharma firm must “specifically describe” awareness of Moderna's work in the mRNA vaccine sphere before the end of the month. 19 September 2023
Big Pharma
Court upholds USPTO and the PTAB decisions over blood-oxygen sensor in smartwatches | Ruling finds Masimo patents to be unpatentable and obvious | Only one claim relating to inconsistency to be reversed. 14 September 2023
Big Pharma
Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma. 12 September 2023
Big Pharma
Healthcare company accuses online sellers of selling unauthorised over-the-counter products | Consumers leave bad reviews after receiving damaged, expired and poor quality goods, says the complaint | Vory, Sater, Seymour and Pease. 5 September 2023
Biotechnology
UN Committee on Racial Discrimination Calls for equitable access to vaccines, treatments, and health tech | Switzerland, Germany, UK, and US refusal to waive IP rights for COVID-19 vaccines 'aids discrimination against vulnerable communities'. 5 September 2023
Big Pharma
Edwards Lifesciences files application for provisional measures at UPC | Hearing details adds to existing listed by the court for 10x Genomics versus NanoString. 31 August 2023
Big Pharma
National Medical Commission has put new regulations on hold that would have made prescribing generics mandatory | Move comes after pressure from doctors’ organisation and pharma firms. 31 August 2023
Big Pharma
Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna. 29 August 2023
Big Pharma
Payments mark the sixth and seventh made to resolve price-fixing charges | Teva donates $50 million in drugs to humanitarian organisations. 24 August 2023
Big Pharma
Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival. 24 August 2023